Pay in 4 interest-free payments of $5.32 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Research involving this compound typically focuses on growth hormone secretagogue and GHRH pathway research, with attention to receptor activity, cellular signaling, and measurable pathway response in experimental models
PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan), while oral tirzepatide is $349/mo month-to-month, or from $279/mo on the 6-month planboth flat rates across commitment tiers with no flat per-compound pricing increases
Last updated: April 2026 | All products for laboratory research use only
## **HCPCS code Q5121 documentation requirements** The billing requirements for HCPCS code Q5121 (injection of infliximab-axxq, biosimilar Avsola, 10 mg) include the following key points: - Report HCPCS Q5121 to document the administration of infliximab-axxq in 10 mg units
US$ 24.55
US$ 23.15
US$ 23.83
US$ 23.93
US$ 25.95
US$ 27.84
US$ 22.15
US$ 21.55
US$ 23.96
